Sharing Results from SORAYA: A Phase III Trial of Mirvetuximab soravtansine in Platinum Resistant, FRα-high Ovarian Cancer

Time: 3:30 pm
day: day 2- pm


  • Discussing efficacy and safety of MIRV in FR-alpha high, platinum resistant ovarian cancer
  • Outlining the evolution of the companion diagnostics and impacts on trials
  • Sharing information about on-going trials and next steps